Leiden, The Netherlands, 26 June 2024 

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, this week presented new data at the 2024 International Society on Thrombosis and Haemostasis (ISTH) Congress, in Bangkok, Thailand.

VarmX was selected by the conference organisers for an oral presentation on the effectiveness of the Company’s lead asset, VMX-C001, in preventing rivaroxaban-induced bleeding in a liver injury model.

VMX-C001 is a modified recombinant human factor X (FX). It is in clinical development for the treatment of severe spontaneous bleeding and the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy.

The data presented by Daniël Verhoef, VarmX’s Director of Research, show that VMX-C001 completely reversed the increase in bleeding time and blood loss induced by treatment with DOAC rivaroxaban in a liver injury model.

Commenting on the new data, Dr. Jan Öhrström, Chairman of VarmX, said: “We are excited to share this new data from a bleeding model confirming that VMX-C001 rapidly restores coagulation in the presence of FXa blood clotting inhibitors. Currently there are very limited treatment options for patients on blood thinning DOACs that suffer severe bleeding or require urgent surgery, making this an important development for patients and physicians across the globe.”

Full details of the presentation, titled OC 43.1 – A novel bleeding model to assess efficacy of VMX-C001 for bypassing of FXa-DOAC anticoagulation, can be found here.

VarmX intends to publish this data in a peer reviewed journal later this year. For further information on the study and results, please contact: info@varmx.com.

Notes to Editors

About VarmX

VarmX is a spin-off from the Leiden University Medical Center (LUMC), founded in 2016 by Professor Pieter Reitsma, a world leading expert in hemostasis and thrombosis. VarmX’s lead compound VMX-C001 is a modified recombinant blood factor X. The compound is being developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The Company is supported by a strong syndicate of investors including Sound Bioventures, EIC, EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures and InnovationQuarter.

For further information, please contact:

Instinctif Partners (media enquiries)

Melanie Toyne-Sewell / Katie Duffell

Tel: +44 20 7457 2020

Email: VarmX@instinctif.com